HPV16 L1 capsid protein expressed from viable adenovirus recombinants elicits neutralizing antibody in mice

Vaccine

Volumn 25, Issue 17, 2007, Pages 3501-3510

  Berg, Michael ^a   Gambhira, Ratish ^b   Siracusa, Mark ^a   Hoiczyk, Egbert ^a   Roden, Richard ^b   Ketner, Gary ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HPV; Immunogenicity; Recombinant adenovirus vaccine

Indexed keywords

ADENOVIRUS VECTOR; NEUTRALIZING ANTIBODY; PROTEIN L1; UNCLASSIFIED DRUG; VIRUS CAPSID ANTIGEN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GENE EXPRESSION; HUMAN PAPILLOMAVIRUS TYPE 16; INFECTION PREVENTION; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; VIRUS GENE; VIRUS LIKE AGENT; VIRUS RECOMBINANT; VIRUS TRANSCRIPTION; VIRUS VIABILITY;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; CAPSID PROTEINS; FEMALE; IMMUNIZATION; MICE; MICE, INBRED BALB C; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; RECOMBINANT PROTEINS; VACCINES, SYNTHETIC; VIRION;

EID: 34047172147     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.06.080     Document Type: Article

References (32)

1. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55 4 (2002) 244-265
2. Bosch F.X., and de Sanjose S. Chapter 1. Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 31 (2003) 3-13
3. Koutsky L.A., Ault K.A., Wheeler C.M., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 21 (2002) 1645-1651
4. Mao C., Koutsky L.A., Ault K.A., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107 1 (2006) 18-27
5. Harper D.M., Franco E.L., Wheeler C., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 9447 (2004) 1757-1765
6. Villa L.L., Costa R.L., Petta C.A., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 5 (2005) 271-278
7. Baud D., Ponci F., Bobst M., De Grandi P., and Nardelli-Haefliger D. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. J Virol 78 23 (2004) 12901-12909
8. Roberts A., Reuter J.D., Wilson J.H., Baldwin S., and Rose J.K. Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein. J Virol 78 6 (2004) 3196-3199
9. Tobery T.W., Smith J.F., Kuklin N., et al. Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques. Vaccine 21 13/14 (2003) 1539-1547
10. Sasagawa T., Tani M., Basha W., et al. A human papillomavirus type 16 vaccine by oral delivery of L1 protein. Virus Res 110 1/2 (2005) 81-90
11. Marais D., Passmore J.A., Maclean J., Rose R., and Williamson A.L. A recombinant human papillomavirus (HPV) type 16 L1-vaccinia virus murine challenge model demonstrates cell-mediated immunity against HPV virus-like particles. J Gen Virol 80 Pt 9 (1999) 2471-2475
12. Hagensee M.E., Carter J.J., Wipf G.C., and Galloway D.A. Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies. Virology 206 1 (1995) 174-182
13. Gaydos C.A., and Gaydos J.C. Adenovirus vaccine. In: Plotkin S.A., and Orenstein M.D. (Eds). Vaccines (2004), Saunders, Philadelphia PA 863-885
14. Berg M., DiFatta J., Hoiczyk E., Schlegel R., and Ketner G. Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit. Proc Natl Acad Sci USA 102 12 (2005) 4590-4595
15. Breitburd F., Kirnbauer R., Hubbert N.L., et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69 6 (1995) 3959-3963
16. Suzich J.A., Ghim S.J., Palmer-Hill F.J., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92 25 (1995) 11553-11557
17. Graham F.L., Smiley J., Russell W.C., and Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36 1 (1977) 59-74
18. Robinson A.J., Younghusband H.B., and Bellett A.J. A circular DNA-protein complex from adenoviruses. Virology 56 1 (1973) 54-69
19. Von Seggern D.J., Chiu C.Y., Fleck S.K., Stewart P.L., and Nemerow G.R. A helper-independent adenovirus vector with E1, E3, and fiber deleted: structure and infectivity of fiberless particles. J Virol 73 2 (1999) 1601-1608
20. Klessig D.F., and Grodzicker T. Mutations that allow human Ad2 and Ad5 to express late genes in monkey cells map in the viral gene encoding the 72 K DNA binding protein. Cell 17 4 (1979) 957-966
21. Klessig D.F., and Hassell J.A. Characterization of a variant of human adenovirus type 2 which multiples efficiently in simian cells. J Virol 28 3 (1978) 945-956
22. Brough D.E., Rice S.A., Sell S., and Klessig D.F. Restricted changes in the adenovirus DNA-binding protein that lead to extended host range or temperature-sensitive phenotypes. J Virol 55 1 (1985) 206-212
23. Buge S.L., Richardson E., Alipanah S., et al. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J Virol 71 11 (1997) 8531-8541
24. Oberg D., Collier B., Zhao X., and Schwartz S. Mutational inactivation of two distinct negative RNA elements in the human papillomavirus type 16 L2 coding region induces production of high levels of L2 in human cells. J Virol 77 21 (2003) 11674-11684
25. Leder C., Kleinschmidt J.A., Wiethe C., and Muller M. Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J Virol 75 19 (2001) 9201-9209
26. Sambrook J., and Russell D.W. Molecular cloning: a laboratory manual (2001), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
27. Ghim S.J., Jenson A.B., and Schlegel R. HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions. Virology 190 1 (1992) 548-552
28. Buck C.B., Pastrana D.V., Lowy D.R., and Schiller J.T. Efficient intracellular assembly of papillomaviral vectors. J Virol 78 2 (2004) 751-757
29. Pastrana D.V., Buck C.B., Pang Y.Y., et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321 2 (2004) 205-216
30. Combita A.L., Touze A., Bousarghin L., Christensen N.D., and Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 76 13 (2002) 6480-6486
31. White W.I., Wilson S.D., Palmer-Hill F.J., et al. Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol 73 6 (1999) 4882-4889
32. Collier B., Oberg D., Zhao X., and Schwartz S. Specific inactivation of inhibitory sequences in the 5′ end of the human papillomavirus type 16 L1 open reading frame results in production of high levels of L1 protein in human epithelial cells. J Virol 76 6 (2002) 2739-2752